These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38040529)

  • 1. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
    Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
    Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis.
    Wang X; Wen D; Chen Y; Ma L; You C
    Cardiovasc Diabetol; 2022 Jun; 21(1):107. PubMed ID: 35706032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis.
    Moustafa B; Oparowski D; Testai S; Guman I; Trifan G
    J Stroke Cerebrovasc Dis; 2024 Apr; 33(4):107633. PubMed ID: 38336118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
    Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
    Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis.
    Zhao Z; Hu X; Zhang Y; Liu D
    J Pharm Pharm Sci; 2020; 23():422-436. PubMed ID: 33137282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials.
    Chiu SW; Pratt CM; Feinn R; Chatterjee S
    J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):409-417. PubMed ID: 32419478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease.
    Delialis D; Dimopoulou MA; Papaioannou M; Kotsira G; Maneta E; Mavraganis G; Loutos C; Georgiopoulos G; Stamatelopoulos K
    Curr Pharm Des; 2023; 29(23):1802-1824. PubMed ID: 37055909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know].
    Corral P; Ruiz AJ
    Hipertens Riesgo Vasc; 2017; 34(4):176-183. PubMed ID: 28709786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors.
    Seijas-Amigo J; Gayoso-Rey M; Mauriz-Montero MJ; Suarez-Artime P; Casas-Martinez A; Dominguez-Guerra M; Gonzalez-Freire L; Estany-Gestal A; Codero-Fort A; Rodriguez-Mañero M; Gonzalez-Juanatey JR;
    Clin Investig Arterioscler; 2022; 34(5):245-252. PubMed ID: 35287972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
    Atia A; Aboeldahab H; Wageeh A; Elneny M; Elmallahy M; Elawfi B; Aboelkhier MM; Elrosasy A; Abdelwahab MM; Sayed S; Abdelaziz A
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):83-102. PubMed ID: 38241002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials.
    Casula M; Olmastroni E; Boccalari MT; Tragni E; Pirillo A; Catapano AL
    Pharmacol Res; 2019 May; 143():143-150. PubMed ID: 30926528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma proprotein convertase subtilisin/kexin type 9 inhibitors and cataract risk: A systematic review and meta-analysis.
    Masson W; Lobo M; Huerín M; Molinero G; Lobo L; Nogueira JP
    Arch Soc Esp Oftalmol (Engl Ed); 2019 Feb; 94(2):75-80. PubMed ID: 30502968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.